Table 2 Highest grade treatment-related Adverse Events (trAE) occurring in ≥10% of patients receiving ENMD-2076.
From: A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
CTCAE v4.0 classification | Any grade N (%) | Grade 3/4 N (%) |
|---|---|---|
Hypertension | 17 (68) | 15 (60) |
Fatigue | 16 (64) | 0 (0) |
Diarrhea | 15 (52) | 1 (4) |
ALT Increased | 12 (48) | 2 (8) |
Hypoalbuminemia | 12 (48) | 0 (0) |
Proteinuria | 12 (48) | 0 (0) |
Dyspepsia | 11 (44) | 0 (0) |
Lymphopenia | 11 (44) | 0 (0) |
Nausea | 11 (44) | 0 (0) |
Thrombocytopenia | 10 (40) | 1 (4) |
AST Increased | 9 (36) | 1 (4) |
Constipation | 8 (32) | 0 (0) |
Xerostomia | 8 (32) | 0 (0) |
Dizziness | 7 (28) | 0 (0) |
Hyponatremia | 7 (28) | 1 (4) |
Mucositis oral | 7 (28) | 0 (0) |
ALP Increased | 6 (24) | 0 (0) |
Headache | 6 (24) | 0 (0) |
Anemia | 5 (20) | 1 (4) |
White blood cell decreased | 5 (20) | 1 (4) |
Edema | 4 (16) | 0 (0) |
Glucose intolerance | 4 (16) | 0 (0) |
Hematuria | 4 (16) | 0 (0) |
Hypomagnesemia | 4 (16) | 0 (0) |
Vomiting | 4 (16) | 0 (0) |
Abdominal pain | 3 (12) | 0 (0) |
Dysgeusia | 3 (12) | 0 (0) |
Flatulence | 3 (12) | 0 (0) |
Hoarseness | 3 (12) | 0 (0) |
Hyperuricemia | 3 (12) | 0 (0) |
Neutrophil count decreased | 3 (12) | 1 (4) |
Palmar-plantar erythrodysesthesia syndrome | 3 (12) | 0 (0) |
Rash maculo-papular | 3 (12) | 0 (0) |
UTI | 3 (12) | 0 (0) |
